KR20080007520A - 피롤-치환된 인돌리논 화합물의 염 및 다형체 - Google Patents

피롤-치환된 인돌리논 화합물의 염 및 다형체 Download PDF

Info

Publication number
KR20080007520A
KR20080007520A KR1020087000428A KR20087000428A KR20080007520A KR 20080007520 A KR20080007520 A KR 20080007520A KR 1020087000428 A KR1020087000428 A KR 1020087000428A KR 20087000428 A KR20087000428 A KR 20087000428A KR 20080007520 A KR20080007520 A KR 20080007520A
Authority
KR
South Korea
Prior art keywords
pyrrole
cancer
fluoro
methyl
ylpropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087000428A
Other languages
English (en)
Korean (ko)
Inventor
안드레이 블라스코
퀸규 진
쿤 루
마이클 안토니 마우라기스
동 송
브렌다 수 본더웰
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20080007520A publication Critical patent/KR20080007520A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020087000428A 2003-10-02 2004-09-20 피롤-치환된 인돌리논 화합물의 염 및 다형체 Ceased KR20080007520A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50810403P 2003-10-02 2003-10-02
US60/508,104 2003-10-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067006363A Division KR20060058728A (ko) 2003-10-02 2004-09-20 피롤-치환된 인돌리논 화합물의 염 및 다형체

Publications (1)

Publication Number Publication Date
KR20080007520A true KR20080007520A (ko) 2008-01-21

Family

ID=34421700

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087000428A Ceased KR20080007520A (ko) 2003-10-02 2004-09-20 피롤-치환된 인돌리논 화합물의 염 및 다형체
KR1020067006363A Ceased KR20060058728A (ko) 2003-10-02 2004-09-20 피롤-치환된 인돌리논 화합물의 염 및 다형체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067006363A Ceased KR20060058728A (ko) 2003-10-02 2004-09-20 피롤-치환된 인돌리논 화합물의 염 및 다형체

Country Status (25)

Country Link
US (1) US7247627B2 (https=)
EP (1) EP1670785B1 (https=)
JP (1) JP4933259B2 (https=)
KR (2) KR20080007520A (https=)
CN (1) CN100432072C (https=)
AR (1) AR047762A1 (https=)
AT (1) ATE473223T1 (https=)
AU (1) AU2004277464B2 (https=)
BR (1) BRPI0415022A (https=)
CA (1) CA2540639C (https=)
CY (1) CY1110771T1 (https=)
DE (1) DE602004028028D1 (https=)
DK (1) DK1670785T3 (https=)
ES (1) ES2348623T3 (https=)
IL (1) IL174414A (https=)
MX (1) MXPA06003661A (https=)
NO (1) NO20061246L (https=)
NZ (1) NZ546001A (https=)
PL (1) PL1670785T3 (https=)
PT (1) PT1670785E (https=)
RU (1) RU2319702C2 (https=)
SI (1) SI1670785T1 (https=)
TW (1) TW200524921A (https=)
WO (1) WO2005033098A1 (https=)
ZA (1) ZA200602691B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
KR20070104673A (ko) * 2005-03-23 2007-10-26 화이자 프로덕츠 인코포레이티드 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
CN101267824A (zh) * 2005-09-20 2008-09-17 辉瑞产品公司 使用酪氨酸激酶抑制剂的治疗剂型和方法
TWI384986B (zh) * 2007-01-17 2013-02-11 Lg Life Sciences Ltd 抗病毒劑之順丁烯二酸單鹽以及含有該單鹽之醫藥組成物
CN101631747B (zh) * 2007-04-04 2012-09-19 大塚化学株式会社 钛酸钾及其制造方法、以及摩擦材料和树脂组合物
US8063043B2 (en) * 2008-09-17 2011-11-22 Novartis Ag Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
RU2430361C1 (ru) * 2010-07-05 2011-09-27 Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет им. В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития диабетической ретинопатии при сахарном диабете типа 2 у якутов
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9851313B2 (en) * 2015-03-03 2017-12-26 Panalytical B.V. Quantitative X-ray analysis—ratio correction

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1575936A3 (ru) * 1986-04-10 1990-06-30 Е.И.Дюпон Де Немур Энд Ко.(Фирма) Способ получени 3,3-дизамещенных индолин-2-ионов или их солей
US5534522A (en) * 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
GEP20063777B (en) * 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
YU67702A (sh) 2001-09-28 2004-12-31 Pfizer Products Inc. Postupak za dobijanje alkansulfonil piridina
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
EP1476443A2 (en) * 2002-02-15 2004-11-17 PHARMACIA & UPJOHN COMPANY Process for preparing indolinone derivatives
PY0323128A (es) * 2002-09-10 2012-12-03 Pharmacia Italia Spa Formulacion sólida que comprende un compuesto de indolina, útil en el tratamiento de trastornos relacionados con proteina de quinasas

Also Published As

Publication number Publication date
ATE473223T1 (de) 2010-07-15
DK1670785T3 (da) 2010-10-18
AU2004277464A1 (en) 2005-04-14
CY1110771T1 (el) 2015-06-10
JP4933259B2 (ja) 2012-05-16
AR047762A1 (es) 2006-02-22
PT1670785E (pt) 2010-09-16
PL1670785T3 (pl) 2010-12-31
SI1670785T1 (sl) 2010-10-29
WO2005033098A8 (en) 2006-04-20
JP2007507482A (ja) 2007-03-29
RU2006110541A (ru) 2006-08-27
IL174414A0 (en) 2008-02-09
MXPA06003661A (es) 2006-06-05
CN100432072C (zh) 2008-11-12
CA2540639C (en) 2010-08-31
EP1670785B1 (en) 2010-07-07
DE602004028028D1 (de) 2010-08-19
CA2540639A1 (en) 2005-04-14
BRPI0415022A (pt) 2006-11-28
HK1093068A1 (zh) 2007-02-23
ZA200602691B (en) 2007-06-27
AU2004277464B2 (en) 2010-07-08
US7247627B2 (en) 2007-07-24
IL174414A (en) 2011-12-29
WO2005033098A9 (en) 2006-05-26
NZ546001A (en) 2009-09-25
RU2319702C2 (ru) 2008-03-20
CN1863796A (zh) 2006-11-15
WO2005033098A1 (en) 2005-04-14
KR20060058728A (ko) 2006-05-30
TW200524921A (en) 2005-08-01
NO20061246L (no) 2006-03-29
ES2348623T3 (es) 2010-12-09
US20050118255A1 (en) 2005-06-02
EP1670785A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
US10278974B2 (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
US20060100198A1 (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-ce]indol-6-one
KR20070060145A (ko) 6-[2-(메틸카바모일)페닐설파닐]-3-ｅ-[2-(피리딘-2-일)에테닐]인다졸의 다형체 형태
KR20080007520A (ko) 피롤-치환된 인돌리논 화합물의 염 및 다형체
AU2006277742B2 (en) Salts and polymorphs of a VEGF-R inhibitor
HK1093068B (en) Salts and polymorphs of a pyrrole-substituted indolinone compound
HK1121137A (en) Salts and polymorphs of a vergf-r inhibitor
CN101238118A (zh) Vegf-r抑制剂的盐及多晶型
HK1176617B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080107

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090918

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091109

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20100628

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100831

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100628

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20091109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I